Organon Pharma Indonesia Tbk. vs Lancartama Sejati Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Lancartama Sejati Tbk. trades at Rp194 (market cap 235.2B, 610.9K 24h volume). The key difference: Lancartama Sejati Tbk. is far larger — about 2.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TAMA | |
|---|---|---|
Market Cap | 104.4B | 235.2B |
Volume | — | 610.9K |
Lot | — | 6.11K |
Turnover | — | 118.47M |
Average Price | — | 193.92 |
Value | — | 118.47M |
Indicative Equilibrium Price | — | 194 |
Indicative Equilibrium Volume | — | 868 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Lancartama Sejati Tbk (the Company) was established based on notary deed No. 12 dated June 01, 1990 of Sugiri Kadarisman, SH., notary in Jakarta.
Read more on TAMA →